In addition to these findings our transcriptional analysis of PS and PG treated cells identified other responding genes that may warrant follow-up work, including KCNJ2, which has previously been associated with modulation of both cell growth and drug resistance [41] and the MYC oncogene, which is a well-known transcriptional target of MAPK signaling which is previously reported to be over-expressed in gliomas [42, 43]. The gene discussed is KCNJ2; the disease is glioma.